TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03913221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate 5 mg/kg
Description: Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate 10 mg/kg
Description: Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
Study: NCT04261439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIZ985
Description: NIZ985 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIZ985
Description: NIZ985 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab infusion
Study: NCT02905097

Intervention type: PROCEDURE
Intervention: Knee Replacement
Description: Surgical replacement of arthritic knee with an implant
Study: NCT00074711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Phosphate
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
Study: NCT03808116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartBx
Description: he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process.
Study: NCT04480489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR
Study: NCT03260881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide Pen Injector [Victoza]
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching liraglutide-placebo pre-filled pens
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Study: NCT02457390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CE-LUS
Description: To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure.
Study: NCT01881191

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI
Study: NCT02571712

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03% plus timolol 0.5%
Description: 1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
Study: NCT01809938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black tea
Description: 300ml of tea without milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tea with milk
Description: 250ml of black tea with 50ml of full fat milk
Study: NCT03560882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablet, 80mg
Study: NCT00297219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate calcium
Description: 1.25 mmol/L dialysate calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dialysate calcium
Description: 1.75 mmol/L dialysate calcium
Study: NCT02910817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00713609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel
Description: 5% benzoyl peroxide in a gel applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide gel
Description: 5% benzoyl peroxide in a gel applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide gel
Description: 5% benzoyl peroxide in a gel applied topically once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin gel
Description: 1% clindamycin phosphate applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin gel
Description: 1% clindamycin phosphate applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin gel
Description: 1% clindamycin phosphate applied topically once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel is an identical gel without the active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel is an identical gel without the active ingredients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is an identical cream without the active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is an identical cream without the active ingredients
Study: NCT01917617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)
Description: Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine , Cisplatin
Description: Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more.
Study: NCT00060528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human GM-CSF
Study: NCT01449162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: 6 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01274949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Description: Low intensity shock wave treatment - 12 sessions
Study: NCT03188016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Interaction with Music
Description: Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intensive Interaction
Description: Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
Study: NCT01166139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna)
Description: Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
Study: NCT02587221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Description: 1 dose approximately 0.5 mL of aQIV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Influenza Comparator (Boostrix)
Description: 1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
Study: NCT00241384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pd-103
Study: NCT00499486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
Study: NCT03028233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Parenting
Description: A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
Study: NCT04477265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate 5mg/tab daily
Description: participants will be taking oral medication for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5mg/tab daily
Description: participants will be taking oral medication for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback-assisted pelvic floor muscle training
Description: participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback-assisted pelvic floor muscle training
Description: participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
Study: NCT04730908

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH
Study: NCT05238077

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
Description: Patients will have different kinds of light shined on different areas
Study: NCT00771394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin hydrochloride
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin hydrochloride
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral
Study: NCT01879111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-targeted feedback
Description: Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
Study: NCT03383601

Intervention type: OTHER
Intervention: Heated Tobacco product IQOS/heatstick
Description: Heated Tobacco Products: heatsticks heated by iQOS device

Intervention type: OTHER
Intervention: Smoking combustible cigarettes
Description: Current smoking of combustible cigarettes
Study: NCT01277744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Peritoneal Perfusion (HIPEC)
Description: HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
Study: NCT01140308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoEnzyme Q10
Description: Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
Study: NCT03688269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Description: Intravenous injection of 8mg/2ml dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Intravenous injection of 2ml Saline 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine
Description: Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perineural ropivacaine
Description: Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
Study: NCT01622439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
Study: NCT02065830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO
Description: The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training.
Study: NCT04506840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
Study: NCT01723241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration A
Study: NCT00903604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: Three 10-minutes infusions of sequential ascending dosages of AP214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 10-minutes infusions of isotonic saline solution
Study: NCT01723241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03870919

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option.

Intervention type: OTHER
Group type: OTHER
Intervention: locoregional treatment
Description: After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
Study: NCT01242735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: 12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
Study: NCT03918850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injection
Description: Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Sublingual Product
Description: Sublingual buprenorphine (BUP-SL), administered daily.
Study: NCT04662905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: ECAP-controlled, closed-loop SCS
Study: NCT02083471

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Specific Oral Tolerance Induction with Egg or Cow's milk
Study: NCT05234411

Intervention type: OTHER
Intervention: Evaluation of ketogenic diet impact on ketonemia
Description: Ketonemia and glycemia levels monitoring during different phases of menstrual cycles